Navigation Links
Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
Date:4/22/2013

trin hormones found in a biological fluid sample such as blood. It allows oncologists to identify and target patients who will receive the greatest benefit from treatment with PAS. Slowing tumor growth, improving quality of life, and extending survival for patients suffering from a gastrin hormone-mediated disease are all accomplishments that Cancer Advances has continually strived toward in its research.

“Cancer Advances continues to produce products that progress our efforts in the fight against gastrin-related diseases,” says Lynda Sutton, president of Cancer Advances.

For more information, please contact:
Lynda Sutton
President, Cancer Advances
lsutton(at)cato(dot)com
919-361-2162
http://www.canceradvancesinc.com

About Cancer Advances
Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html

# # #

Read the full story at http://www.prweb.com/releases/2013/4/prweb10630275.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that it will ... open on Tuesday, April 28, 2015. United ... 28, 2015, at 9:00 a.m. Eastern Time.  The teleconference ... 1-970-315-0533.  A rebroadcast of the teleconference will be available ...
(Date:4/21/2015)... 21, 2015 A leading manufacturer of ... slated to discuss its custom fabrication services today at ... website, which launched just prior to the INTERPHEX event. ... 21, 22 and 23) at the Javits Center in ... the world’s largest and most innovative pharmaceutical and biotech ...
(Date:4/20/2015)... -- Stent retriever thrombectomy, an endovascular technique that ... reduced disability after stroke, according to a groundbreaking ... the Society of Vascular and Interventional Neurology (SVIN).  ... forward that will change the way we approach ... who is associate professor of Neurology and Neurosurgery ...
(Date:4/20/2015)... , April 20, 2015 ... for healing bone injuries. The orthobiologics market is a ... for its stakeholders. The global orthobiologics market report defines ... of revenue. The global orthobiologics market was valued at ... $7,900.2 million by 2019, at a CAGR of 6.7% ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... 2011 HumanTouch, LLC today announced that they were ... Contractors list.   The Fast 50 list ... market conditions and build a sustainable business.  As Washington ... Fast 50 range from resellers to consultants and IT ...
... Resonetics introduces the RapidX250 laser micromachining system, developed ... MEMs and medical devices in a rapid prototype ... devices are fabricated by traditional semiconductor lithography but ... uses a multi-wavelength excimer laser (193nm and 248nm) ...
... Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... Department of Defense (DOD) contract to develop its human ... brain tumors. The research contract, entitled "Research to Treat ... carried out in collaboration with Principal Investigator John Zhang, ...
Cached Biology Technology:RapidX250 Rapid Prototype Tool for Micro Fabrication of Microfluidics, MEMs and Medical Devices 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... for new antibiotics: A new research published in the July ... http://www.fasebj.org ) explains for the first time how honey kills ... that they add to the honey, called defensin-1, which could ... and to develop new drugs that could combat antibiotic-resistant infections. ...
... WEST LAFAYETTE, Ind. - Fast-food restaurants can supersize French ... to supersize a type of apple. Peter Hirst, a ... in some Gala apple trees causes some apples to grow ... reported in the current issue of the Journal of ...
... A drug used to treat rheumatoid arthritis also reduces ... lab research and preliminary findings from a clinical trial of ... clinical study to refine the drug anakinra,s use as an ... Nancy Rothwell will summarise her team,s latest research into both ...
Cached Biology News:Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria 2Apples grow larger when cells don't divide, study shows 2New hope for victims of stroke 2
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
Biology Products: